Yazar "Unal, Caglar" için listeleme
-
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Unal, Caglar; Selcuk, Nalan Alan; Biricik, Fatih Selcuk; Alan, Ozkan; Ordu, Cetin; Selvi, Oguzhan; Sakin, Abdullah (Kare Publ, 2023)Objectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall sur-vival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR), in patients received ... -
Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020-2022)
Unal, Caglar; Tuncer, Gulsah; Copur, Betul; Pilanci, Kezban Nur; Okutur, Kerem Sadi; Yararbas, Kanay; Alan, Ozkan (Taylor & Francis Ltd, 2023)ObjectiveWe aimed to identify a rapid, accurate, and accessible biomarker in the early stages of COVID-19 that can determine the prognosis of the disease in cancer patients.MethodsA total number of 241 patients with solid ... -
The effects of vitamin D (Vit D) replacement on pathological complete response ( PCR) in breast cancer (BC) patients receiving neoadjuvant systemic chemotherapy (NAC).
Ozmen, Vahit; Ordu, Cetin; Ilgun, Ahmet Serkan; Unal, Caglar; Soybir, Gursel; Erdogan, Zeynep; Aktepe, Fatma (Lippincott Williams & Wilkins, 2021)[No Abstract Availale] -
The effects of vitamin D replacement on pathological complete response (pCR) in breast cancer patients receiving neoadjuvant systemic chemotherapy (NAC)
Ozmen, Vahit; Ordu, Cetin; Ilgun, Ahmet Serkan; Unal, Caglar; Soybir, Gursel; Erdogan, Zeynep; Kayan Tapan, Tuba (Wiley, 2021)[No Abstract Availale] -
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
Unal, Caglar; Azizy, Abdulmunir; Karabulut, Senem; Tastekin, Didem; Akyildiz, Arif; Yasar, Serkan; Yalcin, Suayib (Oxford Univ Press, 2023)Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted ... -
Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study
Unal, Caglar; Ordu, Cetin; Ozmen, Tolga; Ilgun, Ahmet Serkan; Celebi, Filiz; Baysal, Buelent; Ozkurt, Enver (Mdpi, 2023)Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive ... -
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
Unal, Caglar; Ozmen, Tolga; Ilgun, Ahmet Serkan; Ordu, Cetin; Ozkurt, Enver; Ak, Naziye; Alco, Gul (Dove Medical Press Ltd, 2023)Background: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and ... -
Metastatic neuroendocrine carcinoma: Liver metastases presenting with diffuse nodular calcifications on CT
Unal, Caglar; Saglam, Sezer (Wolters Kluwer Medknow Publications, 2024)We report a case of the 46-year-old female patient, who presented with diffuse nodular liver calcifications on computed tomography. Histopathology of the calcified nodules revealed neuroendocrine tumors (NETs). Calcified ... -
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
Unal, Caglar; Ozmen, Tolga; Ordu, Cetin; Pilanci, Kezban Nur; Ilgun, Ahmet Serkan; Gokmen, Erhan; Almuradova, Elvina (Frontiers Media Sa, 2023)Background: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed ...
